OpenAI said clinician usage of ChatGPT has already more than doubled over the past year, aligning with wider adoption trends across the industry. According to the American Medical Association, 81% of physicians now report using AI in a professional setting, more than twice the level seen in 2023. The company’s latest move appears designed to capture that growing demand while lowering barriers to entry through free access.
The new tool is positioned as a support system rather than a decision-maker. It helps clinicians handle tasks such as drafting referral letters, generating patient instructions, and conducting medical research, while allowing users to turn repeat workflows into reusable “skills.” A built-in clinical search feature surfaces evidence from “millions of reputable, peer-reviewed medical sources,” according to OpenAI.
To evaluate performance, OpenAI also introduced HealthBench Professional, a benchmark focused on clinical use cases like care consults, documentation, and research. The system uses physician-authored scenarios and multi-stage review to measure both safety and output quality. In internal testing, the company said GPT-5.4 within the clinician workspace outperformed other models, including human physicians on certain evaluated tasks.
Safety remains a central focus in the rollout. OpenAI said physician advisors reviewed more than 700,000 model responses and tested nearly 7,000 real-world conversations before launch. In those trials, doctors rated 99.6% of outputs as safe and accurate. Even so, the company emphasized that the tool is meant to assist clinicians, not replace their expertise.
“ChatGPT for Clinicians is designed to support clinicians with information, not replace their judgment or expertise,” OpenAI wrote in its blog post.
The platform also includes enterprise safeguards such as multi-factor authentication and optional Business Associate Agreements to support HIPAA-compliant workflows when handling protected health information. OpenAI added that conversations are not used to train its models, addressing concerns around data privacy in clinical environments.
The move places OpenAI more directly into competition with a growing field of healthcare AI startups. Companies like Abridge are expanding from transcription into decision support, while others such as OpenEvidence are building specialized clinical assistants and search tools. By offering a free, integrated product tied to its broader ecosystem, OpenAI is betting that ease of access and familiarity will help it gain traction with clinicians before organizations standardize on competing platforms.
As adoption accelerates, the company’s approach suggests a broader shift in strategy: moving beyond general-purpose AI tools toward systems tailored for specific industries. In healthcare, where workflows are tightly regulated and time-constrained, that shift could determine which platforms become embedded in everyday clinical practice.
This analysis is based on reporting from Fierce Healthcare.
Image courtesy of OpenAI.
This article was generated with AI assistance and reviewed for accuracy and quality.
